key: cord-0930971-ti9z2c7j
authors: Snook, Meredith L.; Beigi, Richard H.; Legro, Richard S.; Paules, Catharine I.
title: Should women undergoing in vitro fertilization treatment or who are in the first trimester of pregnancy be vaccinated immediately against COVID-19?
date: 2021-05-14
journal: Fertil Steril
DOI: 10.1016/j.fertnstert.2021.05.083
sha: 847be86b386b2e581da097480749f3e0df6ab049
doc_id: 930971
cord_uid: ti9z2c7j

nan

reproductive age are believed to be pregnant or up 6 weeks postpartum at any given time (3) .

Whereas the overall risk of severe COVID-19 among pregnant women is relatively low to an individual patient, those who get infected and develop symptoms are at increased risk of more severe illness compared with their non-pregnant counterparts. Specifically, pregnant women with symptomatic COVID-19 demonstrate an increased risk of admission to an intensive care unit, need for mechanical ventilation, and death compared with symptomatic non-pregnant individuals (4) (5) (6) (7) . Infection earlier in pregnancy may increase the risk for adverse fetal outcome (8) . Furthermore, a recent systematic review and meta-analysis of 42 studies involving 438,548 pregnancies concluded that SARS-CoV-2 infection may be associated with increased risk of preeclampsia, preterm birth, and stillbirth (9) . As such, the US Centers for Disease Control & Prevention (CDC) considers pregnancy a risk factor for an increased risk of severe illness related to COVID-19 (10) . Therefore, preventing disease in pregnancy, in major part through active vaccination against SARS-CoV-2, and specifically early vaccination either in the periconceptional period or first trimester, is of paramount importance to potentially reduce both maternal and fetal COVID-related morbidity and mortality.

In general, non live-attenuated vaccines are widely utilized and recommended in pregnancy. Maternal immunization through prenatal vaccination has improved maternal and neonatal health for numerous infectious conditions (11) . While the advantage of vaccination during pregnancy sometimes focuses on the potential fetal and infant benefit through passive immunization, the impact of severe maternal infectious disease prevention in pregnancy should not be minimized (12) . This is especially important for respiratory disease prevention, including influenza and COVID-19, of which pregnant women are at heightened risk of adverse outcomes.

Other than live-attenuated vaccines, which are relatively contraindicated in pregnancy, almost all vaccines are permissible in pregnancy (if not actively recommended, like influenza and Tdap) when the benefits are believed to outweigh the risks. The current vaccines developed and demonstrated to have significant potential for prevention of severe infection related to SARS-CoV-2 among the general population undoubtedly will also provide substantial benefit to pregnant individuals. This is the primary reason that the leading professional societies in women's and reproductive health recommend that the vaccine should not be withheld from this population (13) (14) (15) treatment until the second dose has been administered" (15) .

Data from the Development and Reproductive Toxicity (DART) studies regarding use of the approved vaccines are very encouraging. Animal studies demonstrate no increased adverse reproductive effects such as female fertility, embryonic/fetal/post-natal development when these vaccines were delivered pre-mating, or during early or late gestation (19) (20) (21) . The theoretical concept that has grown from unclear sources about vaccines against COVID-19 being linked to infertility is wholly unfounded and has thus been discredited by leading societies in reproductive health (14) .

It is acknowledged that there are relatively limited safety data regarding the use of COVID-19 vaccines in human pregnancy, because the vaccines currently available under the EUA have not yet been tested directly in pregnant women. However, vaccine trials have now commenced in this population. In addition, ongoing safety data that are being collected and reported from the CDC and FDA (i.e. through VAERS, the Vaccine Adverse Event Reporting system) fail to demonstrate any adverse safety signals in regards to pregnancy outcomes or side effect profiles (22, 23) . Specifically, the CDC has established v-safe, an active safety monitoring collected from participants in the v-safe pregnancy registry (among over 500 pregnancies to date) do not indicate any safety concerns with regard to pregnancy and neonatal outcomes (23) .

For additional vaccine safety monitoring, the CDC and FDA co-manage the Vaccine Adverse Event Reporting System (VAERS), an early warning system for identifying possible safety concerns following vaccination including detection of rare adverse effects. Limited by reporting bias, VAERS is not designed to assess for causality nor is there a non-vaccinated control group. Of those adverse events following COVID-19 vaccination in pregnant women reported to VAERS through February 16, 2021, most (73%) involved non-pregnancy specific adverse events (local and systemic reactions) (23) . While miscarriage was the most frequently reported pregnancy-specific adverse event, the rates among women receiving one of the COVID-19 vaccines fall well within published and expected background rates of miscarriage (23, 24) .

Despite the relatively limited data of COVID-19 vaccines in pregnant women, there are also no data suggesting that the vaccines should be contraindicated in this population or in those individuals planning pregnancy. To summarize, the available vaccines against COVID-19 appear to be safe, highly effective in preventing severe illness, and there is no evidence to date that COVID-19 vaccination in the periconception or prenatal period is associated with increased reproductive, pregnancy, or neonatal adverse outcomes compared with background rates. In J o u r n a l P r e -p r o o f this vein, it is recommended that patients undergoing fertility treatment receive vaccination when eligible (15) , either in the periconceptional period or early pregnancy, while adhering to guidance set forth by the ASRM Coronavirus/COVID-19 Task Force to avoid vaccination within three days before or after an elective surgical or fertility-related procedure such as oocyte retrieval, embryo transfer, or intrauterine insemination (25) . This guideline regarding timing considerations is important because known common side effects of vaccines (fever, chills, myalgia, fatigue, etc.) could confuse possible peri-operative evaluation for complications and many facilities may not allow patients to enter or proceed with procedures if they have COVIDlike symptoms, which can be similar to the side effects of vaccines.

The decision to receive the vaccine while undergoing IVF treatment or early in pregnancy should not be weighed solely against the theoretical and "unknown" risk of the vaccine itself, but more so within the context of the real increased risk of adverse outcomes associated with severe COVID-19 illness while pregnant and the known ability of the vaccines to prevent disease. Any delay in taking the vaccine would facilitate pregnant women to incur the risks of contracting and experiencing severe illness and adverse outcomes related to COVID-19 infection, including maternal and fetal death.

Delaying vaccination while undergoing fertility treatment could also lead to an unknown period of delay as fertility and IVF treatments are often not successful on first attempt, and may require numerous attempts to achieve an ongoing pregnancy. Treatment success relies on numerous variables, and despite the clinical team's best attempts, cannot always be predicted.

Of those patients who conceive a successful pregnancy, time to pregnancy after initiation of fertility treatment could be 8-12 months (26, 27) or longer. Some patients will not ever J o u r n a l P r e -p r o o f conceive. Therefore, given the uncertainty surrounding treatment success, it is reasonable to recommend vaccination once eligibility criteria are met and "at the soonest possible time, whether pre-conception or during pregnancy", as supported by ASRM (25) . There is also likely some flexibility with regard to scheduling the vaccine if a patient is in an active treatment cycle, to avoid the 6-day window surrounding a possible procedure, or, there may be the luxury of scheduling the start of a fertility treatment cycle around first and, if needed, second vaccine doses. Additionally, as opposed to other vaccines, the vaccines against SARS-Cov-2 are still serving as a relatively scarce resource and may not always be readily available to specific populations at any given time. Electing to delay vaccination may not mean it is readily available in the future.

Fever, a common side effect of any vaccine, is reported in up to 9% and 16% of individuals following the single dose of the Janssen vaccine (28) or final dose of both mRNA vaccines, respectively (20, 29) . Fever may be of concern in early pregnancy due to an observed association with congenital anomalies (30) , especially neural tube defects, but not in a recent, large cohort study (31) . A causal relationship is also challenging to construct due to retrospective study designs, reporting bias, inconsistency of reported degree/duration of fever, and the fact that fever is typically caused by a response to an underlying infection, and therefore any association with congenital anomalies would need to be distinguished from the effects of fever itself from those related to an underlying infection. Additionally, any association between hyperthermia and congenital anomalies appears to be mitigated in the setting of adequate folic acid intake (30, 32) and single-agent acetaminophen use (33) . The observed fevers following vaccination to COVID-19 are short-lived and it is recommended to take J o u r n a l P r e -p r o o f acetaminophen for alleviation (13) without any perceived risk, advice with which the overwhelming majority of pregnant women will comply.

In conclusion, contraction of SARS-CoV-2 during pregnancy may have devastating maternal and fetal outcomes. Further, emerging data suggest vaccination may lead to maternal antibody transmission to the fetus providing potential protection against infant infection (34) .

Current safety data surrounding the vaccines against COVID-19 are reassuring and do not indicate any safety concerns for individuals who are planning pregnancy or are in the first trimester, while at the same time demonstrate high efficacy in the general population. For those patients undergoing IVF treatment or in early pregnancy, it is in their best interests to strongly consider vaccination once eligible, and sooner rather than later, as they may incur the risk of severe COVID-related illness and associated morbidity and mortality the longer they wait.

Con: A universal recommendation for COVID-19 vaccination in women undergoing in vitro fertilization treatment or who are pregnant is not supported by clinical trial data. Richard S. Legro, M.D. (Fig 3) Catharine I. Paules, M.D. (Fig 4) In this past year we have seen an unprecedented accomplishment of science; the rapid development, testing, and emergency use authorization of highly effective COVID-19 vaccines, Up until the revision of the Common Rule in 2018, "pregnant women" were described as "vulnerable" subjects that required special protection in research studies. While the 2018 revision removed the vulnerable designation, it still listed 10 conditions that must be met before research can be initiated in women who are pregnant (35) . It is the first condition that has been the largest hurdle: preclinical studies in pregnant animals.

J o u r n a l P r e -p r o o f While the term "vulnerable" as an ethical principle to protect women who are pregnant from harmful research has been expunged from the ethical guidance, medical vulnerability has not been incorporated as a scientific justification to escalate the study of these women. As discussed by our colleagues during their "pro" argument, women who are pregnant and develop COVID-19 are at an increased risk for intensive care admission, invasive ventilation, extracorporeal membrane oxygenation and death compared to women who are not pregnant (6) . In addition, there are non-respiratory complications of COVID-19 in pregnant women that must be considered, including an increased risk of venous thromboembolism, hypertensive disorders of pregnancy, preterm delivery and cesarean section (36) . One might argue that the increased risk to women who are pregnant, though suspected at the time when COVID-19 vaccination trials were being designed, was not strong enough to bypass the Common Rule conditions. However, we know from our experiences with other infectious diseases, such as Influenza and Ebola, that women who are pregnant are disproportionately impacted by pandemics and that pregnancy is often a risk factor for infectious disease related morbidity and mortality (37, 38) . Thus, despite a lack of COVID-19 vaccine studies in other adult populations early in the pandemic, it was not only scientifically inappropriate to exclude these women from clinical trial enrollment, it was ethically inequitable. Pregnant women should have be among the first groups studied, rather than relegated to the end of the line.

The second Common Rule hurdle in the first condition remains; the necessity to conduct preclinical studies in pregnant animals to look for embryonic/fetal lethality and anomalies. This (39) . Thalidomide first appeared as an over the counter anti-emetic agent in Germany and was widely used until reports of limb abnormalities emerged. These abnormalities included phocomelia, which was characterized by severe reduction or loss of the proximal long bones with retention of the distal hand/foot plate (40) .

DART studies are routinely performed in animals such as rats and rabbits and may not be entirely generalizable to human populations. It should be noted that thalidomide did not display teratogenic effects in rats and only showed limb abnormalities in rabbits at doses well above those given to people (41) . DART studies also require significant time to complete. In fact, only preliminary DART data were available at the time of the EUA by the FDA of the Pfizer-Biotech and Moderna COVID-19 vaccines (20, 42) . For the Jansen adenovector virus, reproductive toxicity study in female rabbits concluded that the vaccine given prior to mating and during gestation periods at doses up to 2 times human dose did not have any effects on female reproduction, fetal/embryonal development, or postnatal development. (43) The absence of complete DART data, was not seen as a compelling reason to limit access of women who are pregnant to the COVID-19 vaccines under EUA. This leads to the question of why the completion of these DART studies remain a Common Rule and FDA Vaccine Guidance hurdle to clinical trial participation at all, particularly in the setting of a pandemic.

Due to the exclusion of pregnant women from the initial COVID-19 vaccine studies, guidance for COVID-19 vaccination in women who are pregnant is based largely on expert opinion rather than on science. This defaults to a risk-benefit discussion with the individual's physician and one must weigh what is known vs. what is not known to balance decision making. The dilemma for the heirs of Archie Cochrane and practitioners of evidence-based medicine is how to discuss the risk-benefit ratio of COVID-19 vaccination during pregnancy when there are no Level 1 data from randomized trials (44) . However, as the pandemic rages on, is it even possible to take a true "con" side to delaying COVID-19 vaccination of individuals in this high-risk group? In some cases, advising a woman who is pregnant to defer COVID-19 vaccination could be seen as outside their best interests, given the "abundance of data" in other adult populations and the overwhelming support for "not withholding" it from pregnant women by U.S. professional medical societies (45) , (although our own American Society for Reproductive Medicine used intentional language to recommend vaccination) (46) . Yet, despite strong support for recommending COVID-19 vaccines in women who are pregnant, there remain unanswered questions regarding the safety of these vaccines in this group.

Already, we have seen that side effect profiles differ based on the population to which they are administered. Younger individuals report more local and systemic adverse events after the Pfizer-Biontech and Moderna mRNA vaccines than older individuals (47) , while anaphylaxis after these vaccines has been largely seen in individuals with a history of allergies or allergic reactions (48, 49) . Rare but serious side effect, thrombosis with thrombocytopenia syndrome, has been reported after the Janssen adenovirus vector vaccine and is most common in women J o u r n a l P r e -p r o o f <50 years of age. (50) . It is critical, that vaccine safety data in one population not be directly extrapolated to another population.

Caution must be taken when administering COVID-19 vaccines to pregnant women in the absence of these safety data. As more vaccines are given under EUA to women who are pregnant, there will be less incentive to collect data in randomized, double-blind, placebocontrolled clinical trials. Many clinicians will be recommending vaccination to all of the women who qualify for a vaccine study but don't participate, yet allowing a placebo (and withholding the vaccine) to those who do participate. It will, in our opinion, take a particularly enlightened and altruistic person to choose to participate in these trials and accept the possibility of a placebo, when the overwhelming professional position is moving toward a general recommendation for vaccination. In addition, companies may decide not to pursue these studies altogether as enrollment becomes increasingly difficult. In this regard, Pfizer-Biontech has recently suspended enrollment in their COVID-19 vaccine pregnancy study within the United States where COVID-19 vaccines are readily available. were similar to those seen in non-pregnant adults and among 3958 participants who were contacted for further assessment, adverse pregnancy and neonatal outcomes were in line with those reported in other vaccine studies prior to the COVID-19 pandemic. Although these data are reassuring, there are important limitations that must be recognized. One such limitation is the utilization of a historical comparator for pregnancy and neonatal outcomes rather than a placebo control group. The individuals assessed in this observational cohort were largely healthcare workers and likely differ with the historical comparator in terms of age, ethnic group, access to medical care and other characteristics that are known to impact pregnancy and neonatal outcomes. In addition, vaccine safety data in the peri-conception and early pregnancy periods are lacking as there are relatively few of these individuals included in the registry and many of these pregnancies are still ongoing. While useful, observational studies lack the high quality, granular data obtained in placebo-control trials and by basing recommendations solely on these data we accept a lower standard for pregnant versus nonpregnant adults.

In terms of clinical trial participation, we live in a world where personalized medicine is becoming the gold standard. The decision to include women who are pregnant in initial studies of new vaccines must be individually adjudicated based on the severity and threat of the illness.

There must be a way to bypass the current infrastructure that is scientifically determined and allows the ethically sound design and implementation of clinical trials in women who are pregnant.

The executive branch of the federal government has the power to modify the CFR and guidances to industry. One key priority is a modification of the Common Rule to remove existing roadblocks to studying women who are pregnant in circumstances, such as a pandemic. This could be achieved by adding an 11 th item to Subpart B of the Common Rule: Even with modifications to the Common rule, the potential liability to industry and other stakeholders from any reproductive toxicity that resulted from accelerated, modified or omitted DART testing or early enrollment in clinical trials before completion of trials in other adults will remain a hurdle. Expansion of programs or legislative initiatives which mitigate liability when vaccine development is a public health priority will speed vaccine development for women who are pregnant in future pandemics (52) . One current example is the Countermeasures Injury Compensation Program, which provides compensation for women who are pregnant and other individuals not pregnant who are harmed by products designed to prevent or treat public health threats such as COVID-19 (53) . Ultimately COVID-19 vaccination in pregnancy illustrates a human rights issues in which a category of adults has been systematically deprived of the opportunity to participate in research or make medical decisions based on evidence because of a natural condition.

We have seen the concept of "separate but equal" for school segregation rejected by the Discriminatory laws and policies must be supported by an "exceedingly persuasive justification" that is substantially related to an important government objective and cannot be based on stereotypes about gender roles (54) . Applying the Equal Protection Clause may be the key to increasing access of woman who are pregnant (or capable of pregnancy) to research participation.

The systematic exclusion of women who are pregnant (or at risk for pregnancy) from vaccine trials has resulted in unequal and inferior treatment. Calls for greater inclusion of women, J o u r n a l P r e -p r o o f including women who are pregnant, in clinical trials is overwhelming and has been advocated exhaustively by experts (55), task forces (51), working groups(56, 57) (including one authored by our opponent in this debate, Dr. Beigi) (58), professional organizations (59) and the National Academy of Medicine (60) . Women who are pregnant do not need protection against participating in vaccine trials. They can make informed decisions. In 2021 the only "exceedingly persuasive justification" is for the inclusion of women who are pregnant in COVID-19 vaccine trials at the same time as other adults.

Providers of care to women who are pregnant are obligated to advocate for fair and equitable treatments for their patients. How can we as clinicians and researchers make recommendations to our patients who are pregnant without scientific proof of safety and efficacy and how can we, if we are proponents of equal rights, allow the systemic exclusion of women who are pregnant from the pivotal vaccination trials? The two concepts of medical research that require evidence for all and access to all are inextricably linked. Are we going to accept that COVID-19 vaccines are safe and effective during pregnancy based on observational data or do we insist on adequately powered prospective placebo-controlled randomized trial such as the ones that led to the FDA EUAs of vaccines in other adult populations?

Are we as providers upholding equal rights or perpetuating a "separate but equal" arrangement whereby vaccines and medications will be tested in women who are pregnant at some J o u r n a l P r e -p r o o f indeterminate point in the future according to some lesser clinical study standard or maybe not at all due to an inability to complete trials when clinical practice has moved beyond the question? If women who are pregnant are being asked to make an informed decision about whether to receive a COVID-19 vaccine under EUA with insufficient pregnancy data, why is it believed that they cannot make an informed decision to participate in a research study of these vaccines in the same absence of data? In a public health emergency where women who are pregnant are at increased risk for severe illness and mortality, the doctrine of delayed and "separate but equal" clinical trials for women who are pregnant is inherently unequal. The COVID-19 pandemic has given us the opportunity and the imperative to advocate for change, so that during the next pandemic there is only a "pro" argument for vaccination of pregnant women! J o u r n a l P r e -p r o o f

H1N1 2009 influenza virus infection during pregnancy in the USA

Use of contraception and use of family planning services in the Unites States

Characteristics and Maternal and Birth Outcomes of Hospitalized Pregnant Women with Laboratory-Confirmed COVID-19 -COVID-NET, 13 States

SARS-CoV-2 Infection Among Hospitalized Pregnant Women: Reasons for Admission and Pregnancy Characteristics-Eight US Health Care Centers

Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status-United States

Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis

Risk factors associated with adverse fetal outcomes in pregnancies affected by Coronavirus disease 2019 (COVID-19): a secondary analysis of the WAPM study on COVID-19

The impact of COVID-19 on pregnancy outcomes: a systematic review and meta-analysis

COVID-19): people with certain medical conditions

Vaccination During Pregnancy

Maternal benefits of immunization during pregnancy

American College of Obstetricians and Gynecologists' Immunization, Infectious Disease, and Public Health Preparedness Expert Work Group. ACOG Practice Advisory. Vaccinating Pregnant and Lactating Patients Against COVID-19

Medical Experts Continue to Assert that COVID Vaccines Do Not Impact Fertility

Coronavirus/COVID-19 Task Force of the American Society for Reproductive Medicine. ASRM Patient Management and Clinical Recommendations During the Coronavirus (COVID-19) Pandemic UPDATE No. 11-COVID-19 Vaccination December

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Overview of Janssen's Single-Dose COVID-19 Vaccine

Emergency Use Authorization (EUA) of the Pfizer-Biontech COVID-19 vaccine to prevent Coronavirus Disease 2019 (COVID-19)

FDA briefing document: Moderna COVID-19 vaccine

Emergency use authorization (EUA) of the Janssen COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19)

V-safe COVID-19 Vaccine Pregnancy Registry

COVID-19 vaccine safety update

Early Pregnancy Loss

Coronavirus/COVID-19 Task Force of the American Society for Reproductive Medicine. ASRM Patient Management and Clinical Recommendations During the Coronavirus (COVID-19) Pandemic UPDATE No. 13-Variants, Vaccines, and Vaccination

A randomized clinical trial to evaluate optimal treatment for unexplained infertility: the fast track and standard treatment (FASTT) trial

A randomized clinical trial to determine optimal infertility treatment in older couples: the Forty and Over Treatment Trial (FORT-T)

JNJ-78436735) sponsor briefing document. Vaccines and Related Biological Products Advisory Committee meeting

FDA briefing document: Pfizer-BioNTech COVID-19 vaccine

Systematic review and meta-analyses: fever in pregnancy and health impacts in the offspring

Fever in pregnancy and risk of congenital malformations: a cohort study

Periconceptional maternal fever, folic acid intake, and the risk for neural tube defects

Acetaminophen use in pregnancy and risk of birth defects: findings from the National Birth Defects Prevention Study

COVID-19 vaccine response in pregnant and lactating women: a cohort study

Anonymous. Subpart B -Additional Protections for Pregnant Women, Human Fetuses and Neonates Involved in Research

Disease Severity and Perinatal Outcomes of Pregnant Patients With Coronavirus Disease 2019 (COVID-19)

Pregnant Women and the Ebola Crisis

Effects of influenza on pregnant women and infants

Thalidomide-induced teratogenesis: history and mechanisms

The teratogenic effects of thalidomide on limbs

Teratogenic Effects of Thalidomide in Rabbits, Rats, Hamsters, and Mice

PF-07302048) VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE BRIEFING DOCUMENT

FDA Briefing Document Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19 Available at

A short history of evidence-based obstetric care

Vaccinating Pregnant and Lactating Patients Against COVID-19. American College of Obstetricans and Gynecologists

American Society for Reproductive Medicine (ASRM) patient management and clinical recommendations during the Coronavirus (COVID-19) pandemic update no. 11 -COVID-19 Vaccination Available at:covidtaskforceupdate11.pdf (asrm.org) Accessed

Reactogenicity Following Receipt of mRNA-Based COVID-19 Vaccines

Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine -United States

Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine -United States

Centers for DIseases COntrol and Prevention. Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States

Task force on research specific to pregnant and lactating women

Increasing the Participation of Pregnant Women in Clinical Trials

Involving Pregnant Individuals in Clinical Research on COVID-19 Vaccines

Reed at 40: A Landmark Decision

Inclusion of Pregnant and Lactating Persons in COVID-19 Vaccination Efforts

Pregnant women & vaccines against emerging epidemic threats: Ethics guidance for preparedness, research, and response

Equity in coronavirus disease 2019 vaccine development and deployment

The need for inclusion of pregnant women in COVID-19 vaccine trials

Committee Opinion No. 646: Ethical Considerations for Including Women as Research Participants

Women and Health Research: Ethical and Legal Issues of Including Women in Clinical Studies: Volume I